Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies

Published: September 2016
No. of Pages: 112
Single User License: US $ 4995
Corporate User License: US $ 14985

Gastric cancer is characterized by the formation of malignant cells in the inner lining of the stomach, and is the fifth most common cancer globally. Due to its indolent nature it is difficult to treat until it’s more advanced stages and as a result remains one of the most common causes of cancer-related deaths worldwide. The incidence rate of gastric carcinoma is high in East Asia – particularly China and Japan – compared with Western markets. There are many types of gastric cancer, but adenocarcinoma is the most common type, and is diagnosed in 95% of cases.

The Asia-Pacific (APAC) gastric cancer market is forecast to grow from $1.3 billion in 2015 to $2.7 billion in 2022, at a Compound Annual Growth Rate (CAGR) of 11.4%. Gastric cancer is often a neglected cancer, as it tends to develop slowly over many years. The majority of gastric cancer cases are diagnosed in the later stages in the countries focused on in this report, with the exception of Japan, where the majority of cases are diagnosed at the early stages. The high number of cases diagnosed at stage I in Japan can be attributed to the country’s increased levels of awareness and screening for gastric cancer (Orditura et al., 2014).

As per Gayathri Kanika, GBI Research, states: “In line with improved diagnosis rates, the anticipated approval of various monoclonal antibodies (mAbs) over the forecast period will drive treatment rates across all lines of therapy and generate higher sales in the gastric cancer market”.

The current treatment landscape of gastric cancer largely comprises generic chemotherapies. However, chemotherapy provides limited clinical benefit, while causing serious side effects. Herceptin (trastuzumab) is the only marketed targeted therapy, and serves as the standard-of-care first-line treatment for HER2-positive patients – HER2-negative gastric cancer patients still receive chemotherapy regimens as the first-line treatment.

The report “Gastric Cancer Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Prevalence and Launch of Targeted Therapies” provides an introduction to gastric cancer, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, disease staging and prognoses for patients. An analysis of current treatment algorithms and options are also included.

In depth, this report provides the following analysis:

• Detailed analysis of the drugs currently marketed for this indication: trastuzumab, ramucirumab, apatinib, nab-paclitaxel and TS-1. It analyzes key characteristics, covering safety and efficacy, clinical trial outcomes, tolerability, dosing, administration, prices and overall competitive strength. The products are also compared in a comprehensive heat map.

• Analysis of the pipeline for gastric cancer, by stage of development, molecule type, program type, mechanism of action and molecular target.

• Analysis of recent clinical trials in this indication, by enrollment, duration and failure rate. Finally, promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.

• Supplies forecasts for the gastric cancer market, including epidemiology, treatment usage patterns, pricing, and market size, for the 2015–2022 period. The five APAC markets are covered, and data is presented at a country level.

• Provides detailed analysis of key market drivers and barriers for the gastric cancer market.

• Describes the major deals that have taken place in the global gastric cancer market in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value.

Published By: GBI Research
Product Code: GBI Research1571

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: